Dec 27 (Reuters) - Astellas Pharma Inc has bought U.S.-based Xyphos Biosciences Inc to expand its immuno-oncology business, a deal worth up to $665 million including potential development milestones and its second acquisition in as many months.
Japan’s second biggest drugmaker by sales paid $120 million upfront for Xyphos, with the rest milestone payments, the companies said in a statement.
Astellas also said this month it had agreed to purchase Audentes Therapeutics Inc for about $3 billion to expand its push into genetic medicines. The deal is due to close in January.
Reporting by Rocky Swift; Editing by Edwina Gibbs